Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Other financing activities (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Other financing activities for 3 consecutive years, with $927000.0 as the latest value for Q4 2023.

  • Quarterly Other financing activities fell 5.31% to $927000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2023, up 37.46% year-over-year, with the annual reading at $3.8 million for FY2023, 37.46% up from the prior year.
  • Other financing activities for Q4 2023 was $927000.0 at Actinium Pharmaceuticals, up from $921000.0 in the prior quarter.
  • The five-year high for Other financing activities was $1.0 million in Q2 2023, with the low at $376000.0 in Q1 2021.
  • Average Other financing activities over 3 years is $694250.0, with a median of $690000.0 recorded in 2021.
  • The sharpest move saw Other financing activities decreased 7.41% in 2022, then skyrocketed 135.87% in 2023.
  • Over 3 years, Other financing activities stood at $447000.0 in 2021, then soared by 119.02% to $979000.0 in 2022, then dropped by 5.31% to $927000.0 in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $927000.0, $921000.0, and $1.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.